Cytogen Inc
Cytogen, Inc., a biotechnology company, engages in blood cancer cell-based Liquid Biopsy application business in South Korea. The company offers cell isolators that enrich CTCs from human blood and/or body fluid using high density microporous chips; IF stainers, automated immunofluorescent staining system; and cell image analyzers, which help captures immunofluorescent images of cells stained wit… Read more
Cytogen Inc (217330) - Total Assets
Latest total assets as of September 2025: ₩67.68 Billion KRW
Based on the latest financial reports, Cytogen Inc (217330) holds total assets worth ₩67.68 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Cytogen Inc - Total Assets Trend (2014–2024)
This chart illustrates how Cytogen Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Cytogen Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Cytogen Inc's total assets of ₩67.68 Billion consist of 66.3% current assets and 33.7% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩31.20 Billion | 43.1% |
| Accounts Receivable | ₩3.95 Billion | 5.5% |
| Inventory | ₩1.72 Billion | 2.4% |
| Property, Plant & Equipment | ₩6.83 Billion | 9.4% |
| Intangible Assets | ₩8.62 Billion | 11.9% |
| Goodwill | ₩4.83 Billion | 6.7% |
Asset Composition Trend (2014–2024)
This chart illustrates how Cytogen Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cytogen Inc's current assets represent 66.3% of total assets in 2024, an increase from 29.1% in 2014.
- Cash Position: Cash and equivalents constituted 43.1% of total assets in 2024, up from 19.7% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 17.0% of total assets, an increase from 2.0% in 2014.
- Asset Diversification: The largest asset category is cash and equivalents at 43.1% of total assets.
Cytogen Inc Competitors by Total Assets
Key competitors of Cytogen Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
Cytogen Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Cytogen Inc generates 0.15x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Cytogen Inc is currently not profitable relative to its asset base.
Cytogen Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.16 | 11.41 | 19.14 |
| Quick Ratio | 2.92 | 11.16 | 19.14 |
| Cash Ratio | 0.00 | 6.59 | 0.00 |
| Working Capital | ₩29.67 Billion | ₩ 46.37 Billion | ₩ 21.23 Billion |
Cytogen Inc - Advanced Valuation Insights
This section examines the relationship between Cytogen Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.60 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -2.6% |
| Total Assets | ₩72.48 Billion |
| Market Capitalization | $27.02 Million USD |
Valuation Analysis
Below Book Valuation: The market values Cytogen Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Cytogen Inc's assets decreased by 2.6% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Cytogen Inc (2014–2024)
The table below shows the annual total assets of Cytogen Inc from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩72.48 Billion | -2.65% |
| 2023-12-31 | ₩74.45 Billion | +80.61% |
| 2022-12-31 | ₩41.22 Billion | -25.77% |
| 2021-12-31 | ₩55.53 Billion | +96.14% |
| 2020-12-31 | ₩28.31 Billion | +43.59% |
| 2019-12-31 | ₩19.72 Billion | -13.35% |
| 2018-12-31 | ₩22.75 Billion | +300.59% |
| 2017-12-31 | ₩5.68 Billion | +12.21% |
| 2016-12-31 | ₩5.06 Billion | +18.88% |
| 2015-12-31 | ₩4.26 Billion | +107.25% |
| 2014-12-31 | ₩2.05 Billion | -- |